SpectraCure's modern IPDT require both administration of photosensitizers and nonthermal red light (laser) under management of a unique new dosimetry - SpectraCure has developed and patented the software IDOSE® for safe, accurate and efficient cancer IPDT treatment of solid cancer tumors.

Once the photosensitizer is activated by sufficient light in the presence of oxygen, highly reactive, short-lived singlet oxygen and cytotoxic oxygen radicals are generated. Singlet oxygen is a very aggressive chemical species and will very rapidly react with any nearby biomolecules. Ultimately, these destructive reactions will kill cells through apoptosis or necrosis. Therefore, it is critical for accurate dosimetry, IDOSE® controlling the IPDT treatment of solid tumors without damage to healthy tissue. The light is led to the deeper lying tumors via optical fibers.

Photothermal laser therapy is the treatment of lesions by heating of tissue by laser light. Unlike PDT, the method does not rely on the use of a photosensitizing agent, however the photothermal effect can be enhanced by the use of absorbing agents such as nanoparticles. Examples of tumors that are suitable for targeting with interstitial photothermal laser therapy are liver metastases and breast tumors.

SpectraCure's proprietary technology platform for PDT treatment planning and dosimetry - IDOSE® - is directly applicable also for photothermal laser therapy. SpectraCure's patent portfolio for IDOSE® covers all use of photothermal laser therapy in parallel with PDT.